Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp cut its position in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 1.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 202,941 shares of the company’s stock after selling 2,737 shares during the period. Bank of New York Mellon Corp’s holdings in Kura Oncology were worth $1,768,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the company. Suvretta Capital Management LLC lifted its stake in Kura Oncology by 8.2% during the third quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock worth $149,535,000 after purchasing an additional 583,155 shares during the last quarter. Geode Capital Management LLC lifted its stake in Kura Oncology by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock valued at $34,798,000 after buying an additional 41,535 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Kura Oncology by 1.5% in the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company’s stock worth $28,687,000 after purchasing an additional 23,113 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Kura Oncology by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 624,952 shares of the company’s stock worth $12,212,000 after purchasing an additional 14,106 shares during the period. Finally, Alethea Capital Management LLC raised its position in Kura Oncology by 108.2% in the third quarter. Alethea Capital Management LLC now owns 553,542 shares of the company’s stock worth $10,816,000 after acquiring an additional 287,636 shares in the last quarter.

Kura Oncology Trading Down 0.1 %

Shares of NASDAQ KURA opened at $7.84 on Friday. The stock has a market cap of $633.12 million, a price-to-earnings ratio of -3.32 and a beta of 0.85. The business has a 50 day simple moving average of $7.82 and a 200 day simple moving average of $12.43. Kura Oncology, Inc. has a 52 week low of $6.79 and a 52 week high of $23.48. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. On average, research analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock valued at $92,307 over the last 90 days. 5.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

KURA has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a research report on Thursday, February 27th. JMP Securities restated a “market outperform” rating and set a $28.00 price objective on shares of Kura Oncology in a report on Thursday, February 6th. Wedbush restated an “outperform” rating and set a $36.00 price objective on shares of Kura Oncology in a report on Thursday, February 27th. UBS Group cut their price objective on Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Finally, StockNews.com downgraded Kura Oncology from a “buy” rating to a “hold” rating in a report on Tuesday, March 18th. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Kura Oncology currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.50.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.